Hudson

Researchers are studying the effects of two experimental drugs, pozelimab and cemdisiran, in adults aged 50 to 85 who have Geographic Atrophy (GA) caused by Age-related Macular Degeneration (AMD), a condition that affects central vision. The study aims to compare how quickly GA progresses in patients treated with cemdisiran alone, a combination of pozelimab and cemdisiran, or a placebo. Additional goals include monitoring possible side effects, measuring drug levels in the blood, and checking for antibodies that might reduce drug effectiveness or cause side effects. Participants receive subcutaneous injections of either pozelimab combined with cemdisiran, cemdisiran alone, or a placebo. The study is randomized, double-masked, and placebo-controlled, conducted at multiple centers. Treatment schedules and dosing are managed as described in the protocol, with vaccinations for meningococcal and pneumococcal infections required prior to participation. Throughout the study, participants undergo regular clinic visits where eye imaging using Fundus Autofluorescence (FAF) tracks the progression of GA lesion area over 52 weeks. Researchers also monitor safety, side effects, and immune responses, ensuring adherence to study procedures. The main outcome measured is the growth rate of the GA lesion area over one year, helping to evaluate the potential benefits and risks of the study drugs.

Researchers are evaluating a treatment for adults aged 50 and older who have macular neovascularization caused by neovascular age-related macular degeneration (nAMD). This Phase 3 trial compares a single intravitreal injection of 4D-150 with the active control treatment EYLEA (aflibercept). The study aims to assess changes in visual acuity over one year to better understand the effects of these treatments on this eye condition. Participants are randomly assigned to receive either a single dose of 4D-150 injected into the eye on Day 1 or ongoing EYLEA injections at scheduled visits. The study includes adults who have either never received anti-VEGF therapy or have had up to four prior anti-VEGF injections with documented improvement. The condition must be active and confirmed by specialized eye imaging tests before enrollment. Throughout the 52-week study, participants will have regular assessments including vision tests measured by the ETDRS letter score, eye imaging, and clinical evaluations to monitor treatment effects and safety. Researchers will track visual acuity changes from the start of treatment and watch for any adverse effects. The study's main goal is to measure the average change in best corrected visual acuity at one year.